Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on My Health News Nevada.
Press releases published on September 10, 2025
IPG Health expands Influencer ID marketing expertise into Europe
GlobeNewswire
·
September 10, 2025
LONDON, Sept. 10, 2025 (GLOBE NEWSWIRE) -- IPG Health is formally extending its specialist Influencer ID offering into Europe, cementing its ability to amplify trustworthy brand voices using the power of social media influencers. Following success in the …
Asabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financing to Accelerate Commercialization of Colovac®
GlobeNewswire
·
September 10, 2025
BARCELONA, Spain and PARIS and TAMPA, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- SafeHeal®, a medical device innovator transforming colorectal surgery, today announced a €10 million extension of its oversubscribed €35 million Series C financing round. The …
Communiqué de presse : Tzield approuvé en Chine comme premier traitement modificateur de la maladie pour les patients adultes et pédiatriques atteints de diabète de type 1 au stade 2
GlobeNewswire
·
September 10, 2025
Tzield approuvé en Chine comme premier traitement modificateur de la maladie pour les patients adultes et pédiatriques atteints de diabète de type 1 au stade 2 Approbation basée sur l’étude TN-10, qui démontre la capacité du Tzield à retarder l’apparition …
Pharming Group promoted to the Euronext AMX® index
GlobeNewswire
·
September 10, 2025
Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective from …
Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
GlobeNewswire
·
September 10, 2025
Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes Approval based on the TN-10 study, demonstrating Tzield’s ability to delay the onset of stage 3 T1D in adult and pediatric …
Bioversys Reports Corporate Highlights and Key Financials For the First Half 2025
GlobeNewswire
·
September 10, 2025
BV100: successful end of Phase 2 meeting with US FDA following Positive Phase 2 read-out in Ventilator-Associated Bacterial Pneumonia (VABP); Phase 3 on track to initiate in 2025; Formulation patent granted in China, extending BV100 IP protection to over …
Rapport Announces Pricing of Public Offering of Common Stock
GlobeNewswire
·
September 10, 2025
BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for …